Profile avatar
jamesnolan.bsky.social
Lymphoma+Cellular Therapies fellow at Princess Margaret Cancer Centre Toronto 🇨🇦/ Physician Scientist in Lymphoma/Chromatin Biology 🇮🇪
3 posts 357 followers 295 following
Getting Started
Posts 6 Comments 2

🧵 1/ We’re excited to share that our new paper with @adrianbracken.bsky.social lab is out 🎉 In this study (which began over 10 years ago!), we explore the biology of PRC2 and PRC1 in non-dividing cells. We also explore the effects of PRC2 inhibitor drugs on these cells. Here’s what we found👇

submitted 43 days ago • 3 comments

Congrats to @jamesnolan.bsky.social (now at @pmresearch-uhn.bsky.social) on his #ASH24 abstract achievement award for his PhD research @tcddublin.bsky.social! @adrianbracken.bsky.social 🇮🇪🇨🇦 @ash-hematology.bsky.social #Lmsm #ASHKudos

submitted 78 days ago • 1 comment

Looking forward to sharing collaborative work by myself and @dr-chromatin.bsky.social from the labs of @adrianbracken.bsky.social and @conwayer1.bsky.social at #ASH24 in San Diego this week. #hemesky #lymsm please feel free to stop by and share your thoughts.

submitted 83 days ago • 0 comments

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky

submitted 97 days ago • 4 comments

How does PRC1 counteract transcription? See this preview from @adrianbracken.bsky.social and I on an exciting new study from @robklose.bsky.social lab where they show ncPRC1 blocks the early stages of transcription. www.sciencedirect.com/science/arti... @conwayer1.bsky.social for title inspo!

submitted 98 days ago • 1 comment

My colleague @fergutierrezro1 giving an excellent talk at #ESHBMFS2024 on the clinical implications of clonal hematopoiesis in #telomere biology disorders 🧬; dependent on specific mutation with U2AF1, TP53, and chr1+ associated with #MDSsm and #AMLsm.

submitted 102 days ago • 0 comments